

Review of: "[Case Report] Profound Symptom Alleviation in Long-Covid Patients After PAMP-Immunotherapy: Three Case Reports"

Leonardo Milella¹

¹ Ospedale Pediatrico Giovanni XXIII

Potential competing interests: No potential competing interests to declare.

This is a very valuable case report manuscript.

The aim of authors is correct either in presenting their speculations about the matter of discussion then describing the many limitations of the study.

1) From the point of view of data presentation there is a large lack, it is not well explained the protocol of PAMP-immunotherapy administration, the dosages e/o the modality of drug administration, the clinical speculations that led to choose the amount of drug and the number and time delay between administration the per each patient. No table is presented about the monitoring of patient data and response per administration and mild long time from the end of drug from clinical and laboratoristic point of view.

2) Since there is a very strong interference with the "Cytokine Storm Chain", it is my opinion that a valuation of Cytokine levels IL-1, IL-6; IL-10; IL-18; TNF. Presepsin; Epcidin and Procalcitonin should be compulsory in the aim to go further on with speculations.

3) This is a very courageous therapeutical act and as we know it is very difficult to sail in dark waters, but this is the challenge of scientist. I appreciate so much what is, in my opinion, not clearly expressed from authors but that appears at a deep speculation we are a perfect machines and every organ works through a specific philosophic mode of expression.

4) As in 1906 William Osler said: "...in my opinion sometimes patients seem not to die from the aggression of disease but from the body response to it..."

This manuscript goes in that way but from a positive point of view. Leads to use the body production of biological molecules and carrier to get new specific therapies.

I think that to use in-body patients biologic components could be the future of many clinical solutions. Much more if we consider that the "specific patient therapy" is driving very fast medical science.

This manuscript is at a top level because comes with a new idea, but many different pathways need to be approached studying first of all in a different way the human biology.

For this reasons i suggest the acceptance of the manuscript for publication with minor revision i already described

Dr Leonard milella